Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Gemcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 2/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.91 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.91 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.91 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.56 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.56 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.46 |
| ▸ | ALB | P02768 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | CDA | P32320 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcitabine SCHEMBL285130 | 1.00 | PDE3A (0.91) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL17978348 | 1.00 | PDE3A (0.91) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL348218 | 1.00 | PDE3A (0.91) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL28334969 | 0.99 | PDE3A (0.89) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL19137411 | 0.97 | PDE3A (0.85) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL3975223 | 0.97 | PDE3A (0.89) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6761683 | 0.95 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6369622 | 0.95 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL20827751 | 0.95 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12737233 | 0.95 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115708833-A | Application of gemcitabine in preparation of anti-hydatid medicament | 四川大学 | 2023-02-24 | — | — | CN | claimed |
| CN-114796468-A | Gemcitabine compound and CAR-T cell targeting NKG2D ligand for preparing medicine for treating malignant tumor | 深圳宾德生物技术有限公司 | 2022-07-29 | — | — | CN | claimed |
| EP-4746876-A1 | UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER | Katholieke Universiteit Leuven (BE) | 2026-05-27 | — | — | EP | disclosed |
| US-20260125448-A1 | PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING MAGE-A4 ANTIGEN AND METHODS OF USE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260115242-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-30 | — | — | US | disclosed |
| US-12613238-B2 | Diagnostic and prognostic utility of exosomes in immunotherapy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260097049-A1 | CANNABINOID ANALOGS AND METHODS OF USE FOR TREATMENT AND PREVENTION OF CANCER | BLACKSTONE THERAPEUTICS, LLC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12595311-B2 | Chimeric antigen receptors and related methods and compositions for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4716699-A2 | PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING BRACHYURY ANTIGEN AND METHODS OF USE | Board of Regents, The University of Texas System (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260077026-A1 | METHODS FOR TREATING CANCER WITH HYPERACTIVE ADAR ENZYMES | THE UNIVERSITY OF CHICAGO (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260070970-A1 | METHODS AND COMPOSITIONS INVOLVING CHIMERIC BINDING POLYPEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-20030096789-A1 | Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | AVENTIS PHARMA S.A. | 2003-05-22 | — | — | US | disclosed |
| US-20030091574-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2003-05-15 | — | — | US | disclosed |
| EP-1278518-A2 | A COMPOSITION COMPRISING CAMPTOTHECIN AND A PYRIMIDINE DERIVATIVE FOR THE TREATMENT OF CANCER | Aventis Pharma S.A. (FR) | 2003-01-29 | — | — | EP | disclosed |
| US-6503889-B2 | Especially capecitabine, gemcitabine, CPT-11 or pemetrexed | AVENTIS PHARMA S.A. (FR) | 2003-01-07 | — | — | US | disclosed |
| WO-2002076499-A2 | COMBINATION TREATMENT OF PANCREATIC CANCER | APHTON CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020091132-A1 | Composition and method comprising CPT-11 and a pyrimidine derivative for the treatment of cancer | AVENTIS PHARMA, S.A. | 2002-07-11 | — | — | US | disclosed |
| US-20020086812-A1 | Methods and compositions for diagnosis and treatment of cancer | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2002-07-04 | — | — | US | disclosed |
| US-20020068743-A1 | Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | PFIZER ENTERPRISES SARL (LU) | 2002-06-06 | — | — | US | disclosed |
| WO-2001062235-A2 | A COMPOSITION COMPRISING CAMPTOTHECIN AND A PYRIMIDINE DERIVATIVE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA S.A. (FR) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070970-A1 | METHODS AND COMPOSITIONS INVOLVING CHIMERIC BINDING POLYPEPTIDES | IFNG, TNFRSF9, TNFRSF1A | POLA1 470/4885PDE3A 1903/4885PDE4D 1567/4885 |
| US-20260125448-A1 | PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING MAGE-A4 ANTIGEN AND METHODS OF USE | MICA, TAP1, PDCD1LG2 | POLA1 1471/4885PDE3A 4584/4885PDE4D 1647/4885 |
| US-20020068743-A1 | Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | TYMP, TOP1, DPYD | POLA1 91/4885PDE3A 120/4885PDE4D 99/4885 |
| US-12613238-B2 | Diagnostic and prognostic utility of exosomes in immunotherapy | CD274, ICOS, PDCD1 | POLA1 4563/4885PDE3A 4331/4885PDE4D 2045/4885 |
| US-20260115242-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CD274, PDCD1LG2, PDCD1 | POLA1 953/4885PDE3A 4216/4885PDE4D 3026/4885 |
| US-20260077026-A1 | METHODS FOR TREATING CANCER WITH HYPERACTIVE ADAR ENZYMES | ADAR, ADA, APOBEC3A | POLA1 234/4885PDE3A 2405/4885PDE4D 856/4885 |
| US-12595311-B2 | Chimeric antigen receptors and related methods and compositions for the treatment of cancer | TNFRSF9, LIFR, TNFRSF1A | POLA1 1809/4885PDE3A 4257/4885PDE4D 1755/4885 |
| US-20260097049-A1 | CANNABINOID ANALOGS AND METHODS OF USE FOR TREATMENT AND PREVENTION OF CANCER | CNR2, CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | POLA1 3990/4885PDE3A 3608/4885PDE4D 2960/4885 |
| US-20030096789-A1 | Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | TYMP, TOP1, DPYD | POLA1 91/4885PDE3A 120/4885PDE4D 99/4885 |
| US-20020091132-A1 | Composition and method comprising CPT-11 and a pyrimidine derivative for the treatment of cancer | TYMP, TOP1, DPYD | POLA1 102/4885PDE3A 188/4885PDE4D 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.